Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) Stock Price

ELOXStock

$13.03−78.70%52W

Market Cap$52.60M

P/E—

PEG Ratio1.85

Div yield—

Beta3.40

ELOX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)548.18%

Price vs S&P 500 (4W)-22.88%

PEG Ratio1.85

VGM Score34.05

Book Value / Share (Quarterly)$0.84

P/TBV (Annual)6.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)329.96%

Cash Flow / Share (Quarterly)$-1.31

Price vs S&P 500 (YTD)-46.26%

Net Profit Margin (TTM)-3862.50%

EPS (TTM)$-7.06

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-7.06

EPS (Annual)$-0.49

ROI (Annual)-194.09%

Net Profit Margin (5Y Avg)-8945.39%

Cash / Share (Quarterly)$1.25

ROA (Last FY)-113.76%

EBITD / Share (TTM)$-0.08

ROE (5Y Avg)-197.18%

Operating Margin (TTM)-4412.50%

Cash Flow / Share (Annual)$-1.32

P/B Ratio29.03x

P/B Ratio (Quarterly)12.91x

Net Income / Employee (Annual)$-599,500

EV / Revenue (TTM)288.95x

Net Interest Coverage (TTM)-5.51x

ROA (TTM)-44.15%

EPS Incl Extra (Annual)$-0.49

Current Ratio (Annual)0.31x

Quick Ratio (Quarterly)0.45x

3-Month Avg Trading Volume0.05M

52-Week Price Return-78.70%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.66

P/S Ratio (Annual)8.27x

Asset Turnover (Annual)2.14x

52-Week High$23.40

Operating Margin (5Y Avg)-9696.34%

EPS Excl Extra (Annual)$-0.49

Tangible BV CAGR (5Y)-6.55%

26-Week Price Return558.08%

Quick Ratio (Annual)0.28x

13-Week Price Return8.58%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)0.53x

Enterprise Value$46.23M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)76.53%

Revenue / Employee (Annual)$635,900

Pretax Margin (Annual)-49.43%

Cash / Share (Annual)$1.00

3-Month Return Std Dev110.37%

Net Income / Employee (TTM)$-375,400

ROE (Last FY)-298.10%

Net Interest Coverage (Annual)-624.67x

EPS Basic Excl Extra (Annual)$-0.49

Receivables Turnover (TTM)4.00x

Total Debt / Equity (Quarterly)6.76x

EPS Incl Extra (TTM)$-7.06

ROI (TTM)-150.95%

P/S Ratio (TTM)328.72x

Pretax Margin (5Y Avg)-9115.39%

Revenue / Share (Annual)$1.69

Tangible BV / Share (Annual)$2.59

Price vs S&P 500 (52W)-81.38%

Year-to-Date Return-36.81%

5-Day Price Return-6.19%

EPS Normalized (Annual)$-0.49

ROA (5Y Avg)-306.82%

Net Profit Margin (Annual)-49.43%

Month-to-Date Return-14.89%

Cash Flow / Share (TTM)$-8.79

EBITD / Share (Annual)$-0.41

Operating Margin (Annual)-39.20%

LT Debt / Equity (Annual)0.54x

ROI (5Y Avg)-132.25%

LT Debt / Equity (Quarterly)6.14x

EPS Basic Excl Extra (TTM)$-7.06

P/TBV (Quarterly)4.44x

P/B Ratio (Annual)2.72x

Pretax Margin (TTM)-3862.50%

Book Value / Share (Annual)$10.33

Price vs S&P 500 (13W)5.90%

Beta3.40x

Revenue / Share (TTM)$0.00

ROE (TTM)-256.75%

52-Week Low$0.00

vGradeF

mGradeC

vgmGradeD

ELOX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	—	-$0.66	—
Q3 2023	Nov 13, 2023	-$21.67	-$14.41	+33.50%(+$7.26)
Q2 2023	Aug 11, 2023	-$16.94	-$21.56	-27.27%(-$4.62)
Q1 2023	May 12, 2023	-$28.05	-$31.68	-12.94%(-$3.63)
Q4 2022	Mar 31, 2023	-$32.67	-$33.55	-2.69%(-$0.88)

ELOX Analyst Recommendations

Aug 2024

Sep 2024

Aug 2026

Sep 2026

4.29

4.14

4.22

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ELOXEloxx Pharmaceuticals, Inc. Common Stock	F	—	C	328.7x	—	—	—	$13.03
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Eloxx Pharmaceuticals, Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.